Kasey Keller, the USMNT goalkeeper through four FIFA World Cups, discusses his non-Hodgkins lymphoma diagnosis in 2010 and ...
The FDA has removed R/R PCNSL from a Limitations of Use section on the CAR-T product’s label based on positive findings from ...
Discover effective strategies for monitoring and managing CRS toxicity and ICANS, enhancing patient care and reducing burdens ...
News Medical on MSN
FDA label update expands CAR T access for primary CNS lymphoma
Dana-Farber Cancer Institute-led research helped drive an FDA label update for axicabtagene ciloleucel (Yescarta) that removes a prior exclusion for patients with primary central nervous system ...
Updated FDA labeling for Yescarta now includes patients with relapsed or refractory primary CNS lymphoma, expanding treatment options for this group.
Patients with early-stage Hodgkin lymphoma had impressive response rates when treated with a novel combination of therapies—brentuximab vedotin and nivolumab combined with chemotherapy drugs ...
SurvivorNet on MSN
Targeted drug Epkinly is suddenly front & center in lymphoma care: Here’s what patients need to know
The FDA approved Epkinly in combination with other standard lymphoma drugs, rituximab + lenalidomide, for relapsed or ...
MicroRNAs are central regulators of DLBCL biology and show strong potential as minimally invasive biomarkers to improve ...
Discover how Laverdia CA1 (verdinexor) treats canine lymphoma. Learn about the mechanism of action, handling precautions, and ...
"Even though I'm in remission, I feel like cancer's always in the rear-view mirror behind me," the comedian admitted.
Some very unfortunate news coming from the Omnium Gatherum camp, as the band took to social media to announce that their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results